Trials in Baltimore, Maryland
Here are the top 10 medical studies for colorectal cancer in Baltimore, Maryland
Popular Filters
Phase 3 Trials
Monoclonal Antibodies
MK-4280A for Colorectal Cancer
Recruiting2 awardsPhase 3
Washington, District of Columbia
This trial is testing a new combination treatment for patients with advanced colorectal cancer. The treatment aims to boost the immune system's ability to fight cancer more effectively than current options.
Checkpoint Inhibitor
Nivolumab-relatlimab Combo for Colorectal Cancer
Recruiting2 awardsPhase 3
Philadelphia, Pennsylvania
This trial is testing a combination of two drugs, relatlimab and nivolumab, for patients with a certain type of colorectal cancer who haven't responded to other treatments. The drugs help the immune system attack the cancer.
Small Molecule Drug
Sotorasib + Panitumumab for Colorectal Cancer
Recruiting2 awardsPhase 3
Washington, District of Columbia
This trial is testing two doses of sotorasib combined with panitumumab in patients with a specific type of colorectal cancer that has not responded to other treatments. Sotorasib targets a genetic mutation in the cancer cells, while panitumumab helps the immune system attack the cancer. The goal is to see if this combination can help patients live longer without their cancer getting worse.
Chemotherapy Tailored by ctDNA Status for Colon Cancer
Recruiting1 awardPhase 2 & 3
Greenwich, Connecticut
This trial tests if a blood test for cancer DNA can help decide if colon cancer patients need more treatment after surgery. The test looks for cancer DNA in the blood to predict if the cancer might come back and to guide further treatment.
Monoclonal Antibodies
Atezolizumab + Bevacizumab for Gastrointestinal Cancer
Recruiting2 awardsPhase 3
Washington, District of Columbia
This trial will enroll 20 patients with gastrointestinal cancers who have completed all standard treatments but still have evidence of the disease. Patients will receive intravenous atezolizumab and bevacizumab once every 21 days for a maximum of 12 months.
Kinase Inhibitor
XL092 + Atezolizumab vs Regorafenib for Colorectal Cancer
Recruiting2 awardsPhase 3
Fairfax, Virginia
This trial is testing a combination of two drugs, XL092 and atezolizumab, against another treatment in patients with a specific type of colorectal cancer that has spread and not responded to standard treatments. The goal is to see if the new combination can better stop cancer growth and help the immune system fight the cancer.
Trials With No Placebo
Monoclonal Antibodies
MK-4280A for Colorectal Cancer
Recruiting2 awardsPhase 3
Washington, District of Columbia
This trial is testing a new combination treatment for patients with advanced colorectal cancer. The treatment aims to boost the immune system's ability to fight cancer more effectively than current options.
Procedure
ERAS-007 Combination Therapy for Gastrointestinal Cancer
Recruiting1 awardPhase 1 & 2
Baltimore, Maryland
This trial is testing a new drug called ERAS-007 combined with other cancer treatments to see if it is safe and effective for patients with advanced gastrointestinal cancers. The study focuses on patients with specific genetic mutations in their cancer cells, which are often hard to treat. ERAS-007 aims to target these mutations to help stop the cancer from growing.
Monoclonal Antibodies
ABBV-400 for Advanced Solid Cancers
Recruiting1 awardPhase 1
Fairfax, Virginia
This trial tests a new drug called ABBV-400 for adults with advanced cancers. The study aims to find the best dose and see how well it works, both alone and with other treatments. Patients will receive the drug through an IV and be closely monitored for effects and side effects.
HIF-2alpha Inhibitor
Triple Drug Combo for Solid Cancers
Recruiting1 awardPhase 2
Fairfax, Virginia
This trial is testing a new treatment combining three drugs to help patients with difficult-to-treat cancers. The treatment aims to stop cancer growth, help the immune system fight the cancer, and cut off the blood supply to tumors.
Small Molecule Inhibitor
LY3537982 for Cancer
Recruiting1 awardPhase 1 & 2
Fairfax, Virginia
This trial is testing a new drug called LY3537982 in cancer patients with the KRAS G12C mutation. It targets this mutation to stop cancer cells from growing. The study includes patients who haven't responded to other treatments or cannot tolerate them. LY3537982 is a new drug targeting the KRAS G12C mutation, similar to previously approved drugs like sotorasib and adagrasib.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.